Valuation: Relmada Therapeutics, Inc.

Market Cap 539M 474M 442M 406M 760M 51.64B 778M 5.24B 2.05B 25.55B 2.02B 1.98B 88.34B P/E 2026 *
-6.22x
P/E 2027 * -5.18x
Enterprise Value 539M 474M 442M 406M 760M 51.64B 778M 5.24B 2.05B 25.55B 2.02B 1.98B 88.34B EV / Sales 2026 *
-
EV / Sales 2027 * -
Free-Float
97.1%
Yield 2026 *
-
Yield 2027 * -
1 day-1.72%
1 week+2.80%
Current month-25.72%
1 month-26.36%
3 months-30.26%
6 months+31.46%
Current year+6.42%
1 week 4.94
Extreme 4.94
5.36
1 month 4.85
Extreme 4.85
6.97
Current year 3.22
Extreme 3.2205
8
1 year 0.55
Extreme 0.55
8
3 years 0.24
Extreme 0.2404
8
5 years 0.24
Extreme 0.2404
38.68
10 years 0.24
Extreme 0.2404
54
Manager TitleAgeSince
Chief Tech/Sci/R&D Officer 64 26/10/2020
Chief Executive Officer 65 31/03/2012
Director of Finance/CFO 61 08/01/2020
Director TitleAgeSince
Director/Board Member 65 31/03/2012
Chairman 81 14/06/2017
Director/Board Member 67 11/11/2015
Date Insider Type Main position Quantity % Market Cap.
12/12/25 Buy

Chief Financial Officer

839,665 1.1450%
12/12/25 Free

Chairman

164,000 0.2236%
12/12/25 Free

Compliance Officer

828,000 1.1291%
Change 5-day change 1-year change 3-year change Capi.($)
-1.72%+2.80%+721.87%+100.00% 550M
+0.47%+2.27%+50.78%+70.84% 55.01B
+2.83%+0.48%+28.18%+82.59% 54.24B
+0.54%+1.22%-16.62%-13.47% 23.38B
-0.97%-3.30%-1.79%+383.00% 22.57B
-2.59%-1.53%+15.69%-12.38% 20.19B
-2.15%-2.30%+27.27%-31.03% 17.86B
-2.45%-6.81%+25.06%+543.28% 15.5B
-2.09%+0.64%+49.78%+178.74% 14.2B
-3.14%-8.47%+165.37%+292.18% 14.2B
Average -1.04%-0.63%+106.56%+159.37% 23.77B
Weighted average by Cap. -0.07%-0.11%+35.91%+130.69%

Financials

2026 *2027 *
Net sales - -
Net income -82.04M -72.09M -67.29M -61.75M -116M -7.86B -118M -798M -312M -3.89B -308M -301M -13.44B -108M -95M -88.68M -81.38M -152M -10.36B -156M -1.05B -411M -5.12B -406M -397M -17.72B
Net Debt - -
Logo Relmada Therapeutics, Inc.
Relmada Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing therapies for central nervous system (CNS) and metabolic disorders. The Company is focused on the development of esmethadone (d-methadone, dextromethadone, REL-1017), an N-methyl-D-aspartate (NMDA) receptor antagonist. Esmethadone, an isomer of methadone, is a new chemical entity (NCE) that potentially addresses areas of high unmet medical need in the treatment of CNS diseases and other disorders. The Company’s lead program, REL-1017, is a NCE and novel NMDA receptor (NMDAR) channel blocker that preferentially targets hyperactive channels while maintaining physiological glutamatergic neurotransmission. Its lead product candidate, esmethadone, is being developed as a rapidly acting, oral agent for the treatment of depression and other potential indications. Sepranolone is its phase IIb ready neurosteroid developed for the potential treatment of Tourette syndrome and other compulsive disorders.
Employees
17
Date Price Change Volume
29/07/26 US$5.140 -1.72% 1,218,693
28/07/26 US$5.230 +0.58% 1,514,913
27/07/26 US$5.200 +0.39% 899,009
24/07/26 US$5.180 -0.38% 1,650,486
23/07/26 US$5.200 +4.00% 1,425,399
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
6
Last Close Price
5.140USD
Average target price
12.67USD
Spread / Average Target
+146.43%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. RLMD Stock